Management of Chronic Hepatitis B: An Overview

ABSTRACT

Approximately 400 million individuals worldwide have developed chronic hepatitis B after exposure to the hepatitis B virus (HBV). Up to 40% of these will eventually develop serious hepatic complications. Although widespread immunization, improved blood supply testing, and emphasis on safe sex have significantly decreased new HBV infections, the large reservoir of infected individuals (400 million) remains a serious health problem. At present, only two agents are available for the treatment of chronic hepatitis B: interferon alfa and lamivudine. Both are associated with important limitations of efficacy or safety, or both. These limitations and other problems associated with the evaluation of current and investigational therapies for chronic hepatitis B give rise to several key issues in management of HBV: duration of therapy, goals of therapy, need for standardization of the measurement of clinical responses, and definitions of response to therapy. The last two of these key issues are of particular concern. The lack of similarity in study designs, the use of inconsistent definitions of and criteria for therapeutic response, and the lack of uniformity in assays to detect HBV DNA titers hamper consistent evaluations of treatment. Therefore, there is a need for the scientific community to standardize the measures of performance and methods of analysis and reporting of clinical trials for current and new drugs.

KEYWORDS

Interferon - lamivudine - seroconversion - standardization of response - HBV DNA assay

REFERENCES

• 1 Friedman L S. Liver, biliary tract, and pancreas. In: Tierney LM Jr, McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis & Treatment, 39th ed New York: Lange Medical Books/McGraw-Hill 2000 0: 656-697
• 2 Lok A SF, McMahon B J. Chronic hepatitis B.  Hepatology . 2001;  34 1225-1241
• 3 McMahon B J. Hepatocellular carcinoma and viral hepatitis. In: Wilson RA, ed. Viral Hepatitis New York: Marcel Dekker 1997: 315-330
• 4 Lok A S, Heathcote E J, Hoofnagle J H. Management of hepatitis B: 2000-summary of a workshop.  Gastroenterology . 2001;  120 1828-1853
• 5 Lai C L, Wu P C. Antiviral treatment for chronic hepatitis B.  Hong Kong Med J . 1997;  3 289-296
• 6 Beasley R P, Hwang L-Y. Overview on the epidemiology of hepatocellular carcinoma. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral Hepatitis and Liver Disease Baltimore, MD: Williams & Wilkins 1991: 234-237
• 7 Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections.  Gastroenterology . 2000;  118 S83-S103
• 8 Hoofnagle J H, Di Bisceglie M A. The treatment of chronic viral hepatitis.  Drug Therapy . 1997;  336 347-356
• 9 Wong D KH, Cheung A M, O'Rourke K. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis.  Ann Intern Med . 1993;  119 312-323
• 10 Gow P J, Mutimer D. Treatment of chronic hepatitis.  BMJ . 2001;  323 1164-1167
• 11 Di Bisceglie M A. Combination therapy for hepatitis B.  Gut . 2002;  50 443-445
• 12 Schalm S W. Clinical implications of lamivudine resistance by HBV.  Lancet . 1997;  349 3-4
• 13 Lok A SF, Hussain M, Cursano C. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.  Hepatology . 2000;  32 1145-1153
• 14 Lai C-L, Chien R-N, Leung N WY. A one-year trial of lamivudine for chronic hepatitis B.  N Engl J Med . 1998;  339 61-68
• 15 Leung N WY, Lai C L, Chang T-T. Three year lamivudine therapy in chronic HBV (Abst).  J Hepatol . 1999;  30(Suppl 1) 59
• 16 Chang T T, Lai C L, Liaw Y F. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years (Abst).  Antiviral Therapy . 2000;  5(Suppl 1) 44
• 17 Mutimer D, Pillay D, Cook P. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.  J Infect Dis . 2000;  181 713-716
• 18 Tatulli I, Francavilla R, Rizzo G L. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.  J Hepatol . 2001;  35 805-810
• 19 Brunetto M R, Giarin M, Saracco G. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.  Gastroenterology . 1993;  105 845-850
• 20 Pastore G, Santantonio T, Milella M. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.  J Hepatol . 1992;  14 221-225
• 21 Santantonio T, Mazzola M, Iacovazzi T. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine.  J Hepatol . 2000;  23 300-306
• 22 Butterworth L-A, Prior S L, Buda P J, Faoagali J L, Cooksley W GE. Comparison of four methods for quantitative measurement of hepatitis B viral DNA.  J Hepatol . 1996;  24 686-691
• 23 Pawlotsky J-M, Bastie A, Hezode C. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays.  J Virol Methods . 2000;  85 11-21
• 24 Mutimer D. Virological monitoring of new anti-HBV treatment. Presented at the 36th Annual Meeting of the European Association for the Study of the Liver (EASL); April 18-22, 2001; Prague, Czech Republic